BIEX Pitch Deck Teardown: A Micro-Seed Play for Wearable

Executive Summary: The 8-Slide Micro-Seed Deck

The BIEX pitch deck is a minimalist presentation for a health-technology startup focused on sweat analysis. With only eight slides, the deck attempts to bridge the gap between a certified personal trainer's vision and a PhD-backed research project. The company is seeking a modest €60,000 to move from a validated proof-of-concept to a functional MVP. The core value proposition is the ability to detect overtraining and recovery needs through non-invasive sweat monitoring, a niche that sits between traditional heart rate monitors and invasive blood lactate testing.

Slide 1: Title and Branding

The cover slide introduces the BIEX logo—a blue, stylized cross-link—and the tagline "Harness the power of sweat." It identifies Christof Neuman as the presenter, highlighting his credentials as a NASM and ACSM Certified Personal Trainer. The inclusion of the URL (WWW.BIEX.EU) suggests a European base of operations, though no specific headquarters location is listed on the slide.

Slide 2: The Product Workflow

Slide 2, titled "Immediate sweat analysis," uses a simple three-step visual to explain the user experience. The steps are: Exercise (represented by a runner), Measurement (showing a small white patch applied to the skin), and Analysis (showing a user interacting with a smartphone). This slide establishes that the product is a wearable-app ecosystem, though it does not explain how the data is transmitted from the patch to the phone (e.g., NFC, Bluetooth, or optical scanning).

Slide 3: Competitive Landscape

The "Competition" slide uses a standard checkmark grid to compare BIEX against Heart Rate/HRV, Lactate testing, Pen/Paper, and Kinetic sensors. BIEX claims to be the only solution that covers all five categories: Exercise based, Recovery based, Training effect, OT (overtraining) detection before signs and symptoms, and Multiple biomarkers. Notably, it marks HR/HRV with an asterisk for OT detection, implying it is less effective than their proposed sweat analysis. This slide is the only place where the product's functional output—biomarkers—is mentioned, though the specific biomarkers remain unnamed.

Slide 4: The Team and Advisors

The team is split into "Management" and "Advisory." The management consists of Christof Neuman (CEO) and Mark Burnett (Business Development) . The advisory board is significantly larger, featuring six individuals. Key technical roles include Mehis Viru PhD as Lead Researcher and Toomas Neuman PhD as Technology Expert. The presence of three PhDs and three product development specialists (Fabio Comana, Karmen Reinpõld, and Erik Orgu) suggests the company is currently more of a research collective than a fully staffed commercial entity.

Slide 5: Business Model and Pricing Evolution

The business model slide outlines a "Staged Market Entry" over four years. It is a classic price-skimming strategy:

Year 1: Professional trainers and athletes at €15-25 per unit (Daily/weekly use). · Year 2: Fitness professionals and clubs at €10 per unit (Monthly use). · Year 3: Consumer wellness wearables at <€10 per unit (As needed). · Year 4: Expansion into general health applications.

This slide provides a clear roadmap for how the company intends to scale from a high-touch professional tool to a mass-market commodity.

Slide 6: Milestones and Valuation Roadmap

This slide provides a timeline for funding and valuation. It notes that the Proof of Concept is "COMPLETE," citing trials with the 21cc Triathlon club and Sparta fitness club. The current phase is listed as "€60,000 - Raising" for the next 3 months to develop the MVP. Future milestones include a €600,000 raise in 8-12 months for a market-ready product and a Series A of €2-4 million for commercial expansion and the development of a proprietary BIEX measurement device. This implies the current patch might rely on third-party hardware or a simpler chemical reaction.

Slide 7: Go To Market Strategy

The GTM strategy is a linear progression: Product Development (partnering with Universities and Athletic centers) leads to Free Trials (targeting Elite sport clubs and Market Influencers), which eventually leads to Sales (targeting Midlevel trainers and Amateur sports). The bottom of the slide lists target demographics: Triathletes, Runners, Cyclists, Rowers, and Footballers. This is a standard "bottom-up" approach common in sports tech.

Slide 8: The Ask

The final slide, "Call to Action," specifies the ask: €60,000 . The funds are allocated to three goals: Develop MVP, Expand internationally, and Gain early customers. This is an exceptionally low ask for a hardware startup, which may raise questions about the actual complexity of the device or the founders' manufacturing assumptions.

What BIEX Does Well

The deck is highly focused. It does not waste time on fluff or generic market trends. The Staged Market Entry (Slide 5) is a logical way to handle the high cost of new technology by starting with the most price-insensitive users (pros) and scaling down. The Advisory Board (Slide 4) is also a strong point; for a seed-stage company, having three PhDs involved in research and technology provides necessary scientific weight to the claim that sweat can predict overtraining better than heart rate variability.

What is Missing from the BIEX Deck

The most glaring omission is the Problem Slide . While the competitive grid hints at the limitations of current methods, there is no explicit statement of the pain point athletes face. Furthermore, the Technical Specifications are absent. An investor in health-tech needs to know if this is a colorimetric patch (changes color), an electrochemical sensor, or something else. There is also no mention of Intellectual Property ; in the wearable space, patents are the primary defense against larger incumbents like Garmin or Apple. Finally, the Market Size (TAM) is missing, making it difficult to judge if the €2-4 million Series A valuation is realistic.

Founder's Guide: What to Copy and What to Avoid

Copy the Milestone Clarity: Slide 6 is an excellent example of how to map out the relationship between funding rounds, time, and specific business achievements. It tells the investor exactly where their money goes and what the next valuation inflection point looks like.

Avoid the "Vague Biomarker" Trap: If your product is based on science, name the science. Claiming to measure "Multiple biomarkers" without naming them (e.g., Cortisol, Glucose, Sodium) makes the pitch feel like a black box. Founders should always be specific about their core technology to build trust with technical due diligence teams.

Avoid the Micro-Ask: Asking for €60,000 to "develop an MVP, expand internationally, and gain customers" is unrealistic for a hardware product. International expansion alone can cost more than that. Founders should ensure their ask is commensurate with the complexity of their industry; otherwise, they risk looking under-capitalized or naive about operational costs.